Literature DB >> 36243852

AKT Isoforms in the Immune Response in Cancer.

Zayd Ahmad1, Payaningal R Somanath2,3.   

Abstract

AKT is a protein kinase that exists in three isoforms: AKT1, AKT2, and AKT3. Though similar in structure, these isoforms display different effects. AKT is activated downstream of PI3K, and together, this signaling pathway helps regulate cellular processes including cell growth, proliferation, metabolism, survival, and apoptosis. Disruption in these pathways has been associated with disorders including cardiovascular diseases, developmental disorders, inflammatory responses, autoimmune diseases, neurologic disorders, type 2 diabetes, and several cancers. In cancer, deregulation in the PI3K/AKT pathway can be manifested as tumorigenesis, pathological angiogenesis, and metastasis. Increased activity has been correlated with tumor progression and resistance to cancer treatments. Recent studies have suggested that inhibition of the PI3K/AKT pathway plays a significant role in the development, expansion, and proliferation of cells of the immune system. Additionally, AKT has been found to play an important role in differentiating regulatory T cells, activating B cells, and augmenting tumor immunosurveillance. This emphasizes AKT as a potential target for inhibition in cancer therapy. This chapter reviews AKT structure and regulation, its different isoforms, its role in immune cells, and its modulation in oncotherapy.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  AKT1; AKT2; AKT3; Cancer; Immunology; Protein kinase B

Mesh:

Substances:

Year:  2022        PMID: 36243852     DOI: 10.1007/978-3-031-06566-8_15

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.737


  149 in total

Review 1.  ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

Authors:  Carlos L Arteaga; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

2.  Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors.

Authors:  M Andjelković; T Jakubowicz; P Cron; X F Ming; J W Han; B A Hemmings
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

Review 3.  Perturbations of the AKT signaling pathway in human cancer.

Authors:  Deborah A Altomare; Joseph R Testa
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

Review 4.  The unconventional role of Akt1 in the advanced cancers and in diabetes-promoted carcinogenesis.

Authors:  Abdulrahman Alwhaibi; Arti Verma; Mir S Adil; Payaningal R Somanath
Journal:  Pharmacol Res       Date:  2019-05-09       Impact factor: 7.658

5.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

Review 6.  T-cell regulation by CD28 and CTLA-4.

Authors:  M L Alegre; K A Frauwirth; C B Thompson
Journal:  Nat Rev Immunol       Date:  2001-12       Impact factor: 53.106

7.  3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase.

Authors:  D R Alessi; M Deak; A Casamayor; F B Caudwell; N Morrice; D G Norman; P Gaffney; C B Reese; C N MacDougall; D Harbison; A Ashworth; M Bownes
Journal:  Curr Biol       Date:  1997-10-01       Impact factor: 10.834

8.  Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.

Authors:  Rasha Abu-Eid; Raed N Samara; Laurent Ozbun; Maher Y Abdalla; Jay A Berzofsky; Kevin M Friedman; Mikayel Mkrtichyan; Samir N Khleif
Journal:  Cancer Immunol Res       Date:  2014-07-30       Impact factor: 11.151

9.  Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line.

Authors:  L E Allen; P A Maher
Journal:  J Cell Physiol       Date:  1993-05       Impact factor: 6.384

10.  Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8+ T-cell proliferation and survival.

Authors:  Rasha Abu Eid; Kevin M Friedman; Mikayel Mkrtichyan; Andrea Walens; William King; John Janik; Samir N Khleif
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.